Pharma Mar (OTCMKTS:PHMMF – Get Free Report) is expected to be announcing its resultson Thursday, October 29th. Analysts expect the company to post earnings of $0.0038 per share and revenue of $55.06 million for the quarter.
Pharma Mar Stock Performance
PHMMF stock opened at $94.60 on Tuesday. The company’s 50-day simple moving average is $93.45 and its 200 day simple moving average is $93.40. Pharma Mar has a 52 week low of $77.41 and a 52 week high of $110.40.
Pharma Mar Company Profile
Pharma Mar, SA is a Spanish biopharmaceutical company focused on discovering, developing and commercializing innovative medicines derived from marine organisms. The company specializes primarily in oncology and maintains a research platform dedicated to identifying novel compounds with potential anticancer activity.
Its principal products include Yondelis (trabectedin), an anticancer treatment used in certain cases of advanced soft-tissue sarcoma and ovarian cancer, and Zepzelca (lurbinectedin), a therapy developed for patients with metastatic small-cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
Featured Stories
- Five stocks we like better than Pharma Mar
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.
